Pakistan · Delayed Price · Currency is PKR Citi Pharma Statistics
Total Valuation
Citi Pharma has a market cap or net worth of PKR 14.17 billion. The enterprise value is 16.93 billion.
| Market Cap | 14.17B |
| Enterprise Value | 16.93B |
Important Dates
The last earnings date was Saturday, October 3, 2026.
| Earnings Date | Oct 3, 2026 |
| Ex-Dividend Date | Oct 17, 2025 |
Share Statistics
Citi Pharma has 228.46 million shares outstanding.
| Current Share Class | 228.46M |
| Shares Outstanding | 228.46M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.61% |
| Owned by Insiders (%) | 38.66% |
| Owned by Institutions (%) | 6.42% |
| Float | 135.64M |
Valuation Ratios
The trailing PE ratio is 17.93.
| PE Ratio | 17.93 |
| Forward PE | n/a |
| PS Ratio | 1.01 |
| PB Ratio | 1.31 |
| P/TBV Ratio | 1.31 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 87.46 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 21.42 |
| EV / Sales | 1.20 |
| EV / EBITDA | 7.89 |
| EV / EBIT | 8.72 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.25, with a Debt / Equity ratio of 0.29.
| Current Ratio | 1.25 |
| Quick Ratio | 0.58 |
| Debt / Equity | 0.29 |
| Debt / EBITDA | 1.44 |
| Debt / FCF | n/a |
| Interest Coverage | 5.18 |
Financial Efficiency
Return on equity (ROE) is 7.28% and return on invested capital (ROIC) is 8.21%.
| Return on Equity (ROE) | 7.28% |
| Return on Assets (ROA) | 6.61% |
| Return on Invested Capital (ROIC) | 8.21% |
| Return on Capital Employed (ROCE) | 17.16% |
| Weighted Average Cost of Capital (WACC) | 6.53% |
| Revenue Per Employee | 25.69M |
| Profits Per Employee | 1.44M |
| Employee Count | 548 |
| Asset Turnover | 0.77 |
| Inventory Turnover | 3.04 |
Taxes
In the past 12 months, Citi Pharma has paid 554.18 million in taxes.
| Income Tax | 554.18M |
| Effective Tax Rate | 41.22% |
Stock Price Statistics
The stock price has decreased by -34.74% in the last 52 weeks. The beta is 0.39, so Citi Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.39 |
| 52-Week Price Change | -34.74% |
| 50-Day Moving Average | 71.91 |
| 200-Day Moving Average | 78.13 |
| Relative Strength Index (RSI) | 22.12 |
| Average Volume (20 Days) | 701,075 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Citi Pharma had revenue of PKR 14.08 billion and earned 790.33 million in profits. Earnings per share was 3.46.
| Revenue | 14.08B |
| Gross Profit | 2.47B |
| Operating Income | 1.94B |
| Pretax Income | 1.34B |
| Net Income | 790.33M |
| EBITDA | 2.12B |
| EBIT | 1.94B |
| Earnings Per Share (EPS) | 3.46 |
Balance Sheet
The company has 348.24 million in cash and 3.10 billion in debt, with a net cash position of -2.75 billion or -12.04 per share.
| Cash & Cash Equivalents | 348.24M |
| Total Debt | 3.10B |
| Net Cash | -2.75B |
| Net Cash Per Share | -12.04 |
| Equity (Book Value) | 10.83B |
| Book Value Per Share | 47.42 |
| Working Capital | 1.77B |
Cash Flow
In the last 12 months, operating cash flow was 162.06 million and capital expenditures -706.69 million, giving a free cash flow of -544.63 million.
| Operating Cash Flow | 162.06M |
| Capital Expenditures | -706.69M |
| Depreciation & Amortization | 183.06M |
| Net Borrowing | 82.18M |
| Free Cash Flow | -544.63M |
| FCF Per Share | -2.38 |
Margins
Gross margin is 17.57%, with operating and profit margins of 13.79% and 5.61%.
| Gross Margin | 17.57% |
| Operating Margin | 13.79% |
| Pretax Margin | 9.55% |
| Profit Margin | 5.61% |
| EBITDA Margin | 15.09% |
| EBIT Margin | 13.79% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 3.50, which amounts to a dividend yield of 5.64%.
| Dividend Per Share | 3.50 |
| Dividend Yield | 5.64% |
| Dividend Growth (YoY) | 7.69% |
| Years of Dividend Growth | 3 |
| Payout Ratio | 101.25% |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | 5.64% |
| Earnings Yield | 5.58% |
| FCF Yield | -3.84% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on October 18, 2021. It was a forward split with a ratio of 1.1.
| Last Split Date | Oct 18, 2021 |
| Split Type | Forward |
| Split Ratio | 1.1 |
Scores
Citi Pharma has an Altman Z-Score of 2.94 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.94 |
| Piotroski F-Score | 4 |